Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Repare Therapeutics Inc (RPTX)
NASDAQ:RPTX
Holding RPTX?
Track your performance easily
RPTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.71 - $8.49
Previous Close$3.48
Volume38.73K
Average Volume (3M)105.69K
Market Cap
$147.71M
Enterprise Value-$58.24M
Total Cash (Recent Filing)$208.12M
Total Debt (Recent Filing)$2.17M
Price to Earnings (P/E)―
Beta1.85
Next Earnings
Nov 06, 2024EPS Estimate
-$0.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.63
Shares Outstanding42,445,533
10 Day Avg. Volume66,201
30 Day Avg. Volume105,689
Standard Deviation0.21
R-Squared0.03
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.72
Price to Sales (P/S)2.15
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-2.91
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.67
Forecast
1Y Price Target
$13.71Price Target Upside293.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Repare Therapeutics News
PremiumCompany Announcements
Repare Therapeutics Announces Strategic R&D Focus and Workforce Reduction
PremiumCompany Announcements
Repare Therapeutics Advances Oncology Trials and Preps for 2025Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentsRP-3467 is the potential second-in-class asset among helicase domain inhibitors, where GSK's inhibitor could provide external validation for RPTX's program.
Financial PositionAnother reason to BUY RPTX is valuation: $120M market cap with $208M of cash at June 30 (EV: -$88M).
Strategic OutlookRepare announced a strategic reprioritization of its research and development activities to focus its efforts on the advancement of its portfolio of clinical-stage oncology programs.
Bears Say
Clinical TrialsRisks include negative data from the camonsertib and lunresertib proof-of-concept trials and inability to advance these candidates into later-stage trials.
Regulatory And Market RisksKey risks to the price target include clinical, regulatory, and commercial risks, potential emergence of new competitors, and dilutive financing beyond what has been anticipated.
Stock PerformanceRoche terminating its camonsertib (ATRi) license agreement with Repare in mid-February sent RPTX shares into a nosedive that has reached unwarranted levels.
---
Ownership Overview
4.70% Insiders
0.22% Mutual Funds
0.03% Other Institutional Investors
88.81% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RPTX FAQ
What was Repare Therapeutics Inc’s price range in the past 12 months?
Repare Therapeutics Inc lowest stock price was $2.71 and its highest was $8.49 in the past 12 months.
What is Repare Therapeutics Inc’s market cap?
Currently, no data Available
When is Repare Therapeutics Inc’s upcoming earnings report date?
Repare Therapeutics Inc’s upcoming earnings report date is Nov 06, 2024 which is in 3 days.
How were Repare Therapeutics Inc’s earnings last quarter?
Repare Therapeutics Inc released its earnings results on Aug 06, 2024. The company reported -$0.82 earnings per share for the quarter, beating the consensus estimate of -$0.869 by $0.049.
Is Repare Therapeutics Inc overvalued?
According to Wall Street analysts Repare Therapeutics Inc’s price is currently Undervalued.
Does Repare Therapeutics Inc pay dividends?
Repare Therapeutics Inc does not currently pay dividends.
What is Repare Therapeutics Inc’s EPS estimate?
Repare Therapeutics Inc’s EPS estimate is -$0.87.
How many shares outstanding does Repare Therapeutics Inc have?
Repare Therapeutics Inc has 42,445,534 shares outstanding.
What happened to Repare Therapeutics Inc’s price movement after its last earnings report?
Repare Therapeutics Inc reported an EPS of -$0.82 in its last earnings report, beating expectations of -$0.869. Following the earnings report the stock price went down -8.05%.
Which hedge fund is a major shareholder of Repare Therapeutics Inc?
Among the largest hedge funds holding Repare Therapeutics Inc’s share is Versant Venture Management, LLC. It holds Repare Therapeutics Inc’s shares valued at 9M.
---
Repare Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.71 (293.97% Upside)
$13.71 (293.97% Upside)
Hedge Fund Trend
Decreased
By 74.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.19%
12-Months-Change
Fundamentals
Return on Equity
-30.52%
Trailing 12-Months
Asset Growth
-21.96%
Trailing 12-Months
Company Description
Repare Therapeutics Inc
Repare Therapeutics Inc is a precision oncology company engaged in discovery and development of novel therapeutics. The company use its proprietary, genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Using its SNIPRx platform, it is developing pipeline of SL product candidates, including its product candidate, RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.
---
RPTX Stock 12 Month Forecast
Average Price Target
$13.71
▲(293.97% Upside)
Technical Analysis
Best Analysts Covering RPTX
1 Year
1 Year Success Rate
3/21 ratings generated profit
1 Year Average Return
-30.48%
reiterated a buy rating 10 days ago
Copying Robert Burns's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -30.48% per trade.
---